All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Hemminki, et al. published an article in Blood Cancer Journal on age-specific survival in patients with acute myeloid leukemia (AML) across a 50-year time period (1972–2021), using data from the NORDCAN database, sourced from the cancer registries of Denmark, Finland, Norway, and Sweden. |
Key learnings |
1-, 5/1-, and 5-year relative survival in patients with AML improved in all age groups (0–49 years, 50–59 years, 60–69 years, and 70–79 years), apart from the 80–89 years group. |
Among the Nordic countries, survival rates were highest in Sweden, with 5-year relative survival rates of 80% in the 0–49 years, 70% in the 50–59 years, 45% in the 60–69 years, and 20% in the 70–79 years group.
|
The age-related survival gap widened over time; when comparing the 1972–1976 and 2017–2021 periods, the 5-year relative survival in the 0–49 years group improved from <10% to 60–80%. This improvement decreased successively in each older age-group (50% in the 50–59 years, 30–40% in the 60–69 years, and 19% in the 70–79 years group) to as low as 0–5% in 80–89 year olds. |
In the 70–79 years age group, 1-year survival increased from 10% to >40%; 5-year survival also improved for this age group, particularly in Sweden, likely due to the introduction of treatment guidelines in 2005 recommending initial intensive therapy with cytarabine and anthracycline. |
However, patients aged over 80 years, in whom survival has not improved much over the past 50 years, may benefit from upfront treatment with venetoclax plus hypomethylating agent combination therapy, although survival studies with population-level verification are needed. |
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox